Vertex Pharmaceuticals (VRTX) Intangibles (2009 - 2026)

Vertex Pharmaceuticals' Intangibles history runs 18 years deep, the most recent figure standing at $418.5 million for Q1 2026.

• On a quarterly basis, Intangibles fell 5.15% year-over-year to $418.5 million in Q1 2026; TTM through Mar 2026 was $418.5 million, a 5.15% decrease from a year earlier, with the FY2025 full-year figure at $424.2 million, down 48.64% from the prior year.
• Intangibles declined to $418.5 million in Q1 2026 per VRTX's latest filing, from $424.2 million in the prior quarter.
• Across five years, Intangibles topped out at $839.9 million in Q4 2023 and bottomed at $387.0 million in Q2 2022.
• The 5-year median for Intangibles is $603.6 million (2022), against an average of $595.5 million.
• Across the five-year window, Intangibles soared 55.97% in 2023 and slumped 48.64% in 2025, its largest moves.
• Year by year, Intangibles stood at $603.6 million in 2022, then jumped by 39.15% to $839.9 million in 2023, then retreated by 1.67% to $825.9 million in 2024, then slumped by 48.64% to $424.2 million in 2025, then retreated by 1.34% to $418.5 million in 2026.
• Per Business Quant, the three latest VRTX Intangibles figures stand at $418.5 million (Q1 2026), $424.2 million (Q4 2025), and $429.8 million (Q3 2025).